ACROBiosystems has joined forces with Diagnostic Biochips to speed up neuroscience drug discovery and commercialisation.

ACROBiosystems, through ACRO Certify and under its' Aneuro brand, recently launched in vivo electrophysiology solutions to support its neuroscience research efforts with Diagnostic Biochips.

All in vivo electrophysiology and other neurological drug-development products are available under the Aneuro brand.

These products include pre-formed fibrils, Tau and several other protein antigens linked with neurological diseases.

Electrophysiology plays a vital role in neuroscience research, particularly when trying to understand the neural network.

Monitoring the neuron-level electrical signals and field potential across different brain regions can offer crucial information in decoding neural network function and the biological pathway involved in neurological disease pathology.

The inherent complexity of the neural network makes it difficult to study in vivo electrophysiology.

In addition to data acquisition, the in vivo animal model will be considered which is mainly rodent in nature.

The probes are designed to function without a head stage, while deep-array electrodes come with a 90mm recording depth over 128 channels.

Data acquisition systems in combination with artificial intelligence/cloud-based data analysis software are used to conduct structural and functional analysis of neural circuits, discovery of electrophysiological biomarkers and drug screening.

ACROBiosystems Group, a biotechnology company, works with major pharmaceutical enterprises and several academic institutes to drive research in the biopharmaceutical and health sectors.

Diagnostic Biochips developed a suite of biosensors for medical monitoring. The company’s sensors enable direct and continuous monitoring of compounds such as drugs and biomarkers.